Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3194710 | Clinics in Dermatology | 2012 | 11 Pages |
Abstract
Treatment of pemphigus patients is still challenging and, in some cases, conventional therapy with systemic corticosteroids in combination with adjuvant corticosteroid-sparing immunosuppressive drugs is not sufficient to induce clinical remission. More recently, high-dose intravenous immunoglobulins, immunoadsorption, and the monoclonal anti-CD20 antibody, rituximab, have been established as additional successful therapeutic options. This contribution covers both conventional therapies and most current treatment strategies for pemphigus.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Michael Kasperkiewicz, Enno Schmidt, Detlef Zillikens,